SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is trending as it hits multi-year lows, driven by weak consumer sentiment, intense market competition, and skepticism regarding its ongoing strategic turnaround. While the community is deeply polarized, investors are actively debating whether the current price represents a generational buying opportunity bolstered by a high dividend yield or a continued downward spiral fueled by brand fatigue and leadership concerns.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently a focal point for investors as it approaches its second-quarter earnings report, with the community actively debating whether the company can meet high revenue growth expectations while managing its debt and potential dilution. Traders are heavily focused on the stock's elevated short interest and its potential as a catalyst-driven setup, while long-term shareholders remain locked in a heated discourse regarding management's transparency and the company's long-term execution in the sovereign AI infrastructure market.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors debate the impact of an accelerated lockup expiration, with the community split between concerns over share dilution and optimistic outlooks fueled by the fund's exposure to high-growth AI names like Anthropic and OpenAI. While some retail traders are aggressively accumulating shares expecting a squeeze, others are cautioning about significant volatility and the fund trading at a premium to its net asset value.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies is capturing market attention as its modular edge data center strategy gains traction following a major $500 million hosting agreement with Axe Compute. Investors and the community are actively debating the company's ability to scale infrastructure rapidly while balancing the capital-intensive nature of its expansion and potential future share dilution.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently facing intense pressure as the bond market reacts to rising long-term Treasury yields and persistent concerns over U.S. debt sustainability. Community discussion remains heavily divided, with some investors betting on a long-term rebound driven by fading inflation, while others fear further downside as bond vigilantes challenge the Federal Reserve's control over rates.

Fabrinet engages in the provision of optical packaging and electronic manufacturing services to original equipment manufacturers. The firm's engineering services include process design, failure analysis, reliability testing, tooling design, and real-time traceability system. Its manufacturing operations offer sensors, subsystems, customized optics, and optical modules and components. The company was founded by David Thomas Mitchell on August 12, 1999 and is headquartered in George Town, Cayman Islands.

Fabrinet

Fabrinet is currently trending due to a double-beat on quarterly earnings and upward revisions to guidance, despite some volatility and investor focus on free cash flow metrics. The community is actively debating the stock's valuation and long-term potential within the AI optical packaging and hyperscale infrastructure sector.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist is trending as retail investors rally behind the company's aggressive patent litigation strategy against major memory manufacturers, viewing potential settlement outcomes as a key catalyst for significant valuation growth. Community discussions are highly charged, with long-term shareholders urging others to hold through volatility while highlighting recent analyst target price increases and the strategic importance of the company's patent portfolio in the evolving AI hardware landscape.

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and Renewable Diesel. The Refining segment consists of refining operations, associated marketing activities, and logistics assets that support its refining operations. The Ethanol segment includes its ethanol operations, associated marketing activities, and logistics assets that support its ethanol operations. The Renewable Diesel covers the operations of Diamond Green Diesel Holdings LLC. The company was founded in 1980 and is headquartered in San Antonio, TX.

Valero Energy Corp.

Valero Energy Corp. is trending as investors weigh strong refining margins against volatility in global energy markets and shifting geopolitical pressures. Community discourse remains focused on technical patterns, potential earnings impacts, and the stock's positioning within the broader energy sector.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals is trending as investors position themselves ahead of the upcoming Phase 3 LUCIDITY trial results for avexitide, which is being developed to treat post-bariatric hypoglycemia. Community sentiment is largely bullish, with traders tracking recent analyst upgrades and management's confident stance on the trial's progress.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors react to the company's shift from net selling to significant net buying of equities in the second quarter, highlighted by a $10 billion stake in Alphabet. While the community remains divided between those valuing the company's massive cash pile as a defensive hedge and critics who view its recent performance as stagnant compared to tech-driven market gains, active discussions center on whether new leadership under Greg Abel can successfully deploy capital at scale.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30...

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know

Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.read more...

4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones

As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization. $UPC, $NTHI, $DCOY, $VRDN

Futures Rise As Dip-Buyers Lift Tech Stocks

Futures Rise As Dip-Buyers Lift Tech Stocks

 US equity futures are higher led by Tech as Mag7 leads the group higher and points to a reversal of last week's profit-taking, as traders position for the end of the first half. A shortened week will likely focus on a speech from the Fed's...

Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday

U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutics, Universe Pharmaceuticals for earnings and news.read more...

VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval  

Equity

The FDA approved Viridian’s Lumvoa for the treatment of thyroid eye disease. 


Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze...

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor...

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today...

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

VRDNViridian Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest VRDN News